Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

3(42.9%)

Phase 4

1(14.3%)

N/A

1(14.3%)

Phase 2

1(14.3%)

Phase 3

1(14.3%)

7Total

Phase 1(3)

Phase 4(1)

N/A(1)

Phase 2(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04346693Phase 3Completed

An Open Randomized Study of Dalargin Efectiveness in Combination With Leitragin Drug in Patients With Severe and Critical Manifestations of SARS-COVID-19

Role: lead

NCT04347031Phase 2Completed

A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19

Role: lead

NCT04611841Unknown

Medical-biological Research of the Pathogenesis of COVID-19 Disease Caused by SARS-CoV-2

Role: collaborator

NCT02758912Phase 4Completed

Clinical Study of Medicinal Product Cardionat® Using in Health Athlete Volunteers

Role: lead

NCT03319524Completed

Clinical and Genetic Testing of Patients With Usher Syndrome

Role: collaborator

NCT02293031Not ApplicableUnknown

Gene-activated Matrix for Bone Tissue Repair in Maxillofacial Surgery

Role: collaborator

NCT02145923Phase 1Unknown

Effectiveness and Safety of MMSCs for Enhancing Hematopoietic Recovery and Prophylaxis of Neutropenic Enterocolitis

Role: lead

NCT01889888Phase 1Unknown

Effectiveness and Safety of Autologous Adipose-Derived Regenerative Cells for the Treatment of Urethral Strictures

Role: lead

NCT01850342Phase 1Unknown

Effectiveness and Safety of Cell-Assisted Lipotransfer for the Treatment of Stress Urinary Incontinence

Role: lead

All 9 trials loaded